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Abstract
To identify genetic variants with modest effects on complex human diseases, a growing number of
networks or consortia are created for sharing data from multiple genome-wide association studies
on the same disease or related disorders. A central question in this enterprise is whether to obtain
summary results or individual participant data from relevant studies. We show theoretically and
numerically that meta-analysis of summary results is statistically as efficient as joint analysis of
individual participant data (provided that both analyses are performed properly under the same
modeling assumptions). We illustrate this equivalence with case-control data from the Finland-
United States Investigation of NIDDM Genetics (FUSION) study. Collating only summary results
will increase the number and representativeness of available studies, simplify data collection and
analysis, reduce resource utilization, and accelerate discovery.
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INTRODUCTION
Genome-wide association studies (GWAS) have yielded new findings for many complex
human diseases. Because complex diseases are influenced by an array of genetic variants
mostly with small to moderate effects, it is difficult for one GWAS to provide unequivocal
findings. Indeed, the odds ratios of disease with SNPs that have been observed in GWAS
thus far are typically less than 1.5, and the majority of positive findings have emerged only
after aggressive data sharing across multiple studies. For example, the initial findings from
individual type 2 diabetes GWAS were ambiguous, but a number of disease loci with odds
ratios of 1.1 ~ 1.4 were identified conclusively after combining results from several studies
(Saxena et al. 2007; Zeggini et al. 2007; Scott et al. 2007; Zeggini et al. 2008).
Recognizing the need and benefits of data sharing, GWAS investigators have formed
various networks or consortia to share data on the same disease or related disorders
(Kavvoural and Ioannidis 2008). For example, the Psychiatric GWAS Consortium we are
involved with has enrolled 47 studies in 5 major disorders (The Psychiatric GWAS
Consortium Steering Committee 2009). Some of these consortia have attempted to obtain
raw data on individual participants, as opposed to summary results that are used in
traditional meta-analysis. The raw data from all available studies can then be analyzed
simultaneously. Such analysis is commonly called joint analysis or mega-analysis. We will
use the term mega-analysis and refer to the traditional method of combining summary
results as meta-analysis.
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A major motivation for obtaining raw, individual-level data is the general perception that
mega-analysis is statistically more efficient than meta-analysis since it utilizes much more
detailed information. However, obtaining raw data is difficult, costly and time-consuming.
Some investigators are unwilling or unable to share raw data. For the Tobacco and Genetics
Consortium we are involved with, the majority of the investigators were unable to provide
raw data due to IRB issues and/or study policies that prohibit the sharing of raw data.
Excluding studies that do not contribute raw data will reduce statistical power and limit the
generalizability of the findings. Furthermore, the sheer scale of GWAS data poses
significant practical challenges in storing and analyzing raw data from a large number of
studies.
We show in this article that meta-analysis (when performed properly) is as efficient as
mega-analysis in that the estimates of any genetic effect produced by the two methods have
approximately the same variance. Thus, there is no need to obtain raw data. Even if raw data
are available, one can analyze the data for each study separately and then combine the
summary results through meta-analysis. This will greatly facilitate the analysis, especially if
raw data are available only on a subset of studies.
METHODS
We wish to combine results from K studies with nk participants in the kth study. For the
analysis of each SNP, the data consist of (Yki, Xki), where Yki is the disease status (1 =
disease, 0 = no disease) for the ith participant of the kth study, and Xki is the corresponding
genotype score. (Under the additive mode of inheritance, the genotype score is the number
of minor alleles; under the dominant model, the genotype score indicates, by the values 1
versus 0, whether or not the individual has at least one minor allele; under the recessive
model, the genotype score indicates, by the values 1 versus 0, whether or not the individual
has two minor alleles. For an untyped SNP, the unknown genotype score may be imputed by
the expected genotype score.) We assume the following logistic regression model:
(1)
where the αk’s are study-specific intercepts, and β is the log odds ratio representing a
common genetic effect across studies.
Let β̂k be the maximum likelihood estimate of β by maximizing the likelihood function of
the kth study
and let Vk be the variance estimate of β̂k. Then the inverse-variance meta-analysis estimate
of β is
and its variance is estimated by
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To perform mega-analysis, we obtain the maximum likelihood estimate of β and its variance
estimate by maximizing the joint likelihood function
We show in the Appendix that the meta-analysis and mega-analysis estimates of β have
approximately the same variance, so the two methods have approximately the same
efficiency.
We can add covariates to model (1) in both meta-analysis and mega-analysis. The covariates
may include environmental factors or principal components (Price et al. 2006) used to adjust
for population stratification. The numbers and types of covariates need not be the same
across studies. Meta-analysis of covariate-adjusted genetic effects is approximately as
efficient as mega-analysis using individual-level covariate data (see the Appendix for
details).
If the effects of some covariates are the same across studies, then one can improve the
efficiency of mega-analysis by incorporating this restriction into the joint likelihood function
and thus estimating fewer parameters. However, the efficiency gain is usually minimal
because the number of covariates is much smaller than the sample sizes of typical GWAS.
Interestingly, one can achieve the same efficiency gain by performing a multivariate version
of meta-analysis (see the Appendix for details). The multivariate version of meta-analysis is
not generally recommended because it requires additional summary results and the
assumption of common covariate effects may not be appropriate.
Both meta-analysis and mega-analysis assume a common genetic effect across studies. This
assumption does not affect the validity of association testing since the genetic effects are all
zero under the null hypothesis of no association. However, it is important to determine
whether meta-analysis or mega-analysis is more powerful when the effect sizes are unequal
among studies. We show in the Appendix that the estimates produced by meta-analysis and
mega-analysis are approximately the same and their variance estimates are also
approximately the same when the genetic effects are unequal across studies, so that the two
methods have similar statistical powers.
RESULTS
SIMULATION STUDIES
To demonstrate the equivalence between meta-analysis and mega-analysis, we present here
some simulation results on combining two case-control studies. We simulated data from
model (1), in which the SNP of interest had population minor allele frequencies (MAFs) of
0.3 and 0.2 in studies 1 and 2, respectively, and Xki was the number of minor alleles. We set
α1 = −3, α2 = −2.2, and β = log 1.4. We also considered unequal values of β for the two
studies. Note that eβ pertains to the odds ratio (OR) of disease with the SNP under the
additive mode of inheritance. We obtained various combinations of the numbers of cases
and controls for the two studies. For each combination of the simulation parameters, we
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generated 10 million data sets and performed meta-analysis and mega-analysis of each data
set under model (1). The results are summarized in Table 1.
When the SNP effects are the same between the two studies, the mean estimates of the SNP
effects and the standard errors are identical up to the third decimal point between meta-
analysis and mega-analysis, and the powers are identical up to the second decimal point.
When the SNP effects are different between the two studies, there are some slight
differences between the two methods, and either method can be slightly more powerful than
the other.
FUSION DATA
For illustration with empirical data, we considered the Finland-United States Investigation
of NIDDM Genetics (FUSION) study (Scott et al. 2007). The FUSION study genotyped
1,161 Finnish type 2 diabetes (T2D) cases and 1,174 Finnish normal glucose-tolerant (NGT)
controls on 317,503 SNPs on the Illumina HumanHap300 BeadChip in stage 1 of a two-
stage design. Based on the stage-1 results and the findings of other studies, the study
genotyped 224 SNPs in an additional 1,204 Finnish T2D cases and 1,253 Finnish NGT
controls. The subjects with missing genotypes on a particular SNP were excluded from the
analysis of that SNP. All subjects have age and sex information.
We performed meta-analysis and mega-analysis of T2D status on the 224 SNPs that were
genotyped in both stage 1 and stage 2 of the FUSION study. The results under the additive
mode of inheritance are displayed in Figure 1. The individual estimates of odds ratios vary
considerably between stages 1 and 2. The combined estimates of odds ratios and the
corresponding standard error estimates are virtually identical between meta-analysis and
mega-analysis, and consequently the two sets of p-values are virtually identical. The only
noticeable differences lie in SNPs 114, 166 and 176, which have observed MAFs of
approximately 0.9%, 1.6% and 3.1%. For SNPs with low MAFs, the individual estimates of
genetic effects may be unstable, which may cause the combined estimates to be different
between meta-analysis and mega-analysis. Such differences are unlikely to alter the rankings
of the top SNPs because the p-values associated with rare SNPs tend to be non-significant.
For further illustration, we included age and sex as covariates in the logistic regression
model. When age and sex are allowed to have different effects between stages 1 and 2,
meta-analysis and mega-analysis again produce virtually identical results; see Figure 2.
When age and sex are assumed to have common effects between stages 1 and 2 in mega-
analysis, the results between the two methods are slightly more different; see Figure 3.
DISCUSSION
Publication bias is a major concern in meta-analysis of literature results. One may reduce or
avoid this kind of bias by planning GWAS meta-analysis prospectively to take advantage of
all available studies and all available SNPs. By using summary results rather than raw data,
one can increase the number of available studies and thus enhance the power of the analysis
and the generalizability of the findings.
In many applications, it is desirable to adjust for participant-level covariates, such as
principal components and environmental exposures. Such data are not available in published
reports. In a consortium setting, the covariate adjustments can be made within each study
and the covariate-adjusted estimates of genetic effects can then be combined through meta-
analysis. It is logistically much simpler to provide such adjusted estimates than to transfer
raw data. Indeed, this is the strategy adopted by the Tobacco and Genetics Consortium and
many other consortia. If the covariate effects are the same across studies, then the mega-
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analysis that incorporates that restriction tends to be more efficient than the traditional meta-
analysis. However, the efficiency gain is generally minimal and the same efficiency gain can
be achieved by using a multivariate version of meta-analysis (see the Appendix for details).
We have focused on binary traits. In a related paper, Olkin and Sampson (1998) showed
that, for comparing treatments with respect to a continuous outcome in clinical trials, meta-
analysis is equivalent to mega-analysis if the treatment effects and error variances are
constant across trials. It follows from the arguments of the Appendix that all the conclusions
of this article hold for quantitative traits and indeed for any traits under any study designs;
the details are given in Lin and Zeng (2009).
By working with raw data, one can ensure that all studies use the the same quality-control
criteria and estimate the same quantities. However, such standardization and harmonization
of information can be achieved by requiring all participating investigators to follow a
common set of guidelines on quality control and statistical analysis so that the data are
filtered and analyzed in the same way across studies before summary results are submitted.
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APPENDIX
TECHNICAL DETAILS
We adopt the notation of the Methods section. Let α̂k and β̂k be the maximum likelihood
estimates (MLEs) of αk and β based on the likelihood function of the kth study, and let α̃k
and β̃ be the MLEs of αk and β based on the joint likelihood function. Note that β̃ is the
mega-analysis estimate of β. Write θk = (αk, β), θ̂k = (α̂k, β̂k) and θ̃k = (α̃k, β̃). Also, define
where υki(θk) = eαk + βXki/(1 + eαk + βXki)2. According to the MLE theory (Cox and Hinkley
1979), the variances of β̂k and β̃ are estimated by  and
respectively. The inverse-variance meta-analysis estimate of β is
(2)
and its variance is estimated by
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Note that Var(β̂) takes the same form as Var(β̃): the only difference is that Ik is evaluated at
θ̂k in the former and at θ̃k in the latter. Denote . Under model (1) of the
Methods section, α̂k and α̃k converge to αk while β̂k and β̃ converge to β (as sample sizes nk
increase), so that β̂ also converges to β while Var(n1/2β̂) and Var(n1/2β̃) converge to a
common constant. Thus, n1/2(β̂ − β) and n1/2 (β̃ − β) are asymptotically normal with mean 0
and with a common variance, which implies that meta-analysis and mega-analysis are
asymptotically equivalent.
To accommodate covariates, we extend equation (1) of the Methods section as follows:
(3)
where Zki is the vector of covariates for the ith participant of the kth study, and γk is the
corresponding vector of log odds ratios. By incorporating the unit component into Zki and
the intercept αk into γk, equation (3) can be written in a more compact form
The likelihood functions given in the Methods section are modified to reflect the inclusion
of covariates in the model. Write θk = (β, γk). Let θ̂k and θ̃k denote the MLEs of θk based on
the likelihood function of the kth study and the joint likelihood function, respectively. Then
all the results of the previous paragraph hold with the redefinition of
where .
If the effects of covariates are the same across studies, then equation (3) becomes
(4)
By expanding Xki to include Zki, equation (4) can be written as
in which the vector β represents both the genetic effect and the covariate effects. Redefine
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where υki(θk) = eαk + β
TXki/(1 + eαk + β
TXki)2. By the arguments of the first paragraph, β̂ and β̃
are asymptotically normal with mean β and with a common covariance matrix. Thus,
performing the multivariate version of meta-analysis on the vector of parameters β yields an
estimate of the genetic effect that is asymptotically as efficient as the mega-analysis estimate
when covariate effects are the same across studies.
Because model (3) has K sets of covariate effects whereas model (4) only has one set, mega-
analysis is generally more efficient under model (4) than under model (3). Thus, univariate
meta-analysis, which is asymptotically equivalent to mega-analysis under model (3), is
generally less efficient than mega-analysis under model (4). However, the efficiency loss is
minimal in large samples. Although one can avoid the efficiency loss by performing
multivariate meta-analysis, it is more difficult to obtain multivariate than univariate
summary statistics.
All the above results assume that the genetic effects are the same across studies. This
assumption does not affect the type I error of association testing since all genetic effects are
zero under the null hypothesis of no association. Nevertheless, it is of practical importance
to determine the relative power of meta-analysis versus mega-analysis when genetic effects
are unequal. By taking the differences between the score functions of Lk(αk, β) and
 and applying the mean-value theorem, we can show that
where  lies between θ̂k and θ̃k. Thus, β̃ takes the same form as β̂ shown in equation (2), the
difference being that Ik is evaluated at  in the former and at θ̂k in the latter. As indicated
before, the only difference between Var(β̃) and Var(β̂) is that Ik is evaluated at θ̃k in the
former and at θ̂k in the latter. Note that Ik depends on θk through υki(θk) only. It can be
shown that υki(θk) does not change its values drastically when θk varies between θ̂k and θ̃k in
case-control studies with modest genetic effects. Thus, β̂ and β̃ are approximately the same,
and so are Var(β̂) and Var(β̃). Consequently, the power of meta-analysis is similar to that of
mega-analysis even when genetic effects are unequal across studies.
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Analysis of stages 1 and 2 data from the FUSION study. The top left panel compares the
individual estimates of odds ratios between stages 1 and 2; the top right panel compares the
combined estimates of odds ratios between meta-analysis and mega-analysis; the bottom left
panel compares the standard error estimates between the two methods; and the bottom right
panel compares the − log10(p-values) between the two methods. In each panel, the red line
indicates where the values on the two axes are equal.
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Analysis of stages 1 and 2 data from the FUSION study adjusted for age and sex. The top
left panel compares the individual estimates of odds ratios between stages 1 and 2; the top
right panel compares the combined estimates of odds ratios between meta-analysis and
mega-analysis; the bottom left panel compares the standard error estimates between the two
methods; and the bottom right panel compares the − log10(p-values) between the two
methods. Both meta-analysis and mega-analysis allow age and sex effects to be different
between stages 1 and 2. In each panel, the red line indicates where the values on the two
axes are equal.
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Analysis of stages 1 and 2 data from the FUSION study adjusted for age and sex. The top
left panel compares the individual estimates of odds ratios between stages 1 and 2; the top
right panel compares the combined estimates of odds ratios between meta-analysis and
mega-analysis; the bottom left panel compares the standard error estimates between the two
methods; and the bottom right panel compares the − log10(p-values) between the two
methods. Mega-analysis assumes age and sex effects to be the same between stages 1 and 2
whereas meta-analysis does not. In each panel, the red line indicates where the values on the
two axes are equal.
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